经肝动脉化疗栓塞（TACE）术后肿瘤残余及残癌复发导致肝癌远期疗效不佳。因此，对残癌进行高效诊断并精准治疗是提高疗效的关键。肿瘤微酸性环境可做为肿瘤治疗的靶点，而血管栓塞后缺血缺氧进一步促进了残癌酸性微环境的形成。利用二价锰离子（Mn2+）缩短磁共振（MR）T1弛豫时间及三价砷离子（As3+）的抗肝癌作用，我们设计并构建了酸性细胞穿膜肽标记的酸敏诊疗一体化MnAs纳米药物。预实验显示该纳米药物在体外及小鼠皮下人肝癌移植瘤模型中均具有明显肿瘤抑制作用及MR增强效果。为进一步研究该纳米药物在TACE术后残癌诊疗中的作用，本课题拟采用大鼠原位肝癌模型行TACE治疗，利用经肝动脉精准给药的优势，将酸敏诊疗一体化MnAs纳米药物定向输送至肿瘤组织，旨在促进药物在残癌组织的富集，并以MR活体下进行残癌监测。本项目将提供肝癌TACE术后残癌高效诊断评估、精准治疗的新系统，有望进一步提高肝癌远期疗效。

The residual tumor and tumor recurrence after transcatheter arterial chemoembolization (TACE) lead to poor long-term efficacy. Therefore, to enhance therapeutic efficacy, it's crucial to efficiently diagnose and treat the residual cancer after TACE. Tumor acidic microenvironment can be used as a target for cancer treatment. Additionally, ischemia and hypoxia after vascular embolism further promote the formation of cancer acid microenvironment. Combining Mn2+ that shorten the T1 relaxation time of magnetic resonance (MR) with the anti-HCC effect of As3+, we design and constructed an acidic cell-penetrating peptide labeled acid sensitive integrative MnAs nanodrug. Preliminary experiments show that the nanodrug has obvious human hepatocellular carcinoma inhibitory effect and MRI signal enhancement both in vitro and on mice subcutaneous xenograft models. In order to further understand the role of this nanodrug in the diagnosis and treatment of residual cancer after TACE, this project intends to operate TACE in rat model of liver cancer in situ. Taking advantage of precise administration via hepatic artery, we aim to promote the enrichment of the MnAs nanodrug in the residual tumor tissue and to monitor it with MR in vivo. The success of this project will not only provides a new system for efficient and accurate diagnosis, but also may lead to ultimate treatment of residual cancer after TACE in hepatocellular carcinoma, which is expected to further improve the long-term efficacy.